BioDzhet

Main article: Cancer treatment

2022: Launch of oncopreparations production

At the end of March 2022, it became known that the biotechnology production company BioJet (part of the PharmEco group) received a residence in the Technopolice Moscow special economic zone. At the updated site, the company launches the production of drugs for targeted therapy of cancer.

BioJet invests at least 5 billion rubles in this project. These funds will be used to launch an industrial biopharmaceutical complex with 170 jobs and a production volume of 120 km of active biopharmaceutical substances and up to 5 million bottles of finished product per year.

In the SEZ "Technopolice Moscow" launch the production of oncopreparations for 5 billion rubles

The company will develop and manufacture biotechnological drugs based on monoclonal antibodies in a full cycle, starting from the stage of production of an active pharmaceutical substance. Biotechnological preparations will be developed using DNA recombinant technology or controlled gene expression technology. The advantage of biotechnological drugs is their high specificity to the factors of the onset and development of the disease.

{{quote 'In the special economic zone of Moscow, a biomedical cluster is actively developing, which includes about 30 high-tech enterprises. His new resident will create modern pharmaceutical substances and ready-made medicines of a new generation for the effective therapy of cancer, "said Vladimir Efimov, Deputy Mayor of Moscow for Economic Policy and Property and Land Relations, adding that the new production is focused on the import substitution of drugs for the treatment of cancer. }} According to the SPARK-Interfax system, BioJet was registered in Moscow in the fall of 2021, its authorized capital is 5 million rubles. The organization specializes in the production of medicines.^[1]

Notes